Higher diet quality scores linked to lower emissions but come with trade-offs

The FDA’s de­ci­sion on Rock­et Phar­ma­ceu­ti­cals’ au­tol­o­gous gene ther­a­py for a rare white blood cell dis­or­der has been pushed back by three months to June

Tra­vere Ther­a­peu­tics’ kid­ney dis­ease drug nar­row­ly failed its con­fir­ma­to­ry study sev­en months af­ter it won ac­cel­er­at­ed ap­proval. Tra­vere said Thurs­day it still in­tends to ap­ply